Regulatory news and experts insights.

Un produit peut contenir une substance dangereuse sans nécessairement présenter un risque inacceptable, à condition que l’exposition de l’utilisateur reste maîtrisée. À l’inverse, une faible concentration apparente ne suffit pas toujours à garantir la sécurité. Tout dépend de la toxicité de la substance, de la manière dont elle est libérée, et des conditions réelles d’utilisation.

In response to the public health and environmental challenges posed by endocrine disruptors (EDs), and following two previous national strategies on endocrine disruptors, the French government has unveiled its new roadmap for the next five years with a clear ambition: moving towards “zero exposure to endocrine disruptors”.

Calculating Margins of Safety (MoS) is at the core of cosmetic ingredient safety assessment. On paper, the principle appears simple: comparing a no-effect dose to an estimated exposure in order to verify that a sufficient safety margin exists. In practice, however, things are often far more complex.

The adoption of Directive (EU) 2024/3019 on urban wastewater treatment (UWWTD), published on 12 December 2024, introduces unprecedented requirements for the pharmaceutical industry. Integrated into the EU “Zero Pollution” Action Plan, this legislation imposes stringent management obligations for pharmaceutical residues